His main research concerns Vaccination, Adverse effect, Pediatrics, Immunology and Surgery. His biological study spans a wide range of topics, including Immunization, Incidence, Public health and Risk factor. His Adverse effect study combines topics from a wide range of disciplines, such as Vaccine safety and Intensive care medicine.
His studies in Pediatrics integrate themes in fields like Medical record, Influenza vaccine and Measles-Mumps-Rubella Vaccine. His studies deal with areas such as Global health, Internal medicine and Brentuximab vedotin as well as Surgery. As part of one scientific family, he deals mainly with the area of Internal medicine, narrowing it down to issues related to the Gastroenterology, and often Phases of clinical research and Regimen.
Robert T. Chen mainly focuses on Vaccination, Internal medicine, Immunology, Pediatrics and Adverse effect. His Vaccination research is multidisciplinary, incorporating elements of Epidemiology, Immunization, Incidence and Public health. His Internal medicine research is multidisciplinary, relying on both Gastroenterology, Surgery and Oncology.
His Immunology study frequently draws connections to other fields, such as Virology. Robert T. Chen studied Pediatrics and Diphtheria that intersect with Tetanus. His Adverse effect study incorporates themes from Clinical trial, Vaccine safety and Intensive care medicine.
Robert T. Chen spends much of his time researching Internal medicine, Oncology, Brentuximab vedotin, Lymphoma and Surgery. In Internal medicine, Robert T. Chen works on issues like Gastroenterology, which are connected to Confidence interval, Adverse effect, Anemia, Leukopenia and Performance status. He usually deals with Adverse effect and limits it to topics linked to Vaccine safety and Environmental health.
His research in Oncology intersects with topics in Pembrolizumab, Chemotherapy and Hodgkin lymphoma. His study on Brentuximab vedotin is covered under Immunology. His work carried out in the field of Lymphoma brings together such families of science as Cancer, Cancer research and Hematopoietic stem cell transplantation.
His primary areas of study are Internal medicine, Brentuximab vedotin, Oncology, Gastroenterology and Lymphoma. Internal medicine is closely attributed to Surgery in his research. The concepts of his Brentuximab vedotin study are interwoven with issues in Anaplastic large-cell lymphoma and Antibody-drug conjugate.
His work deals with themes such as Malignancy, Transplantation and Hodgkin lymphoma, which intersect with Oncology. As part of the same scientific family, he usually focuses on Gastroenterology, concentrating on Adverse effect and intersecting with Nausea. Lymphoma is a subfield of Immunology that Robert T. Chen studies.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Anas Younes;Ajay K. Gopal;Scott E. Smith;Stephen M. Ansell.
Journal of Clinical Oncology (2012)
Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland.
Margot Mutsch;Weigong Zhou;Philip Rhodes;Matthias Bopp.
The New England Journal of Medicine (2004)
Impact of anti-vaccine movements on pertussis control: the untold story
E. J. Gangarosa;A. M. Galazka;C. R. Wolfe;L. M. Phillips.
The Lancet (1998)
The Guillain–Barré Syndrome and the 1992–1993 and 1993–1994 Influenza Vaccines
Tamar Lasky;Gina J. Terracciano;Laurence Magder;Carol Lee Koski.
The New England Journal of Medicine (1998)
Measles Antibody: Reevaluation of Protective Titers
Robert T. Chen;Lauri E. Markowitz;Paul Albrecht;John A. Stewart.
The Journal of Infectious Diseases (1990)
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma
Joseph M. Connors;Wojciech Jurczak;David J. Straus;Stephen M. Ansell.
The New England Journal of Medicine (2017)
Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
Weigong Zhou;Vitali Pool;John K Iskander;Roseanne English-Bullard.
Morbidity and Mortality Weekly Report (2003)
The Vaccine Adverse Event Reporting System (VAERS).
Robert T. Chen;Suresh C. Rastogi;John R. Mullen;Scott W. Hayes.
Individual and Community Risks of Measles and Pertussis Associated With Personal Exemptions to Immunization
Daniel R. Feikin;Dennis C. Lezotte;Richard F. Hamman;Daniel A. Salmon.
Evolution of the COVID-19 vaccine development landscape
Tung Thanh Le;Jakob P. Cramer;Robert Chen;Stephen Mayhew.
Nature Reviews Drug Discovery (2020)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: